Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06730542 · ClinicalTrials.gov registry record · Phase 1
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
A Phase 1 study of CNS Lymphoma, sponsored by Juan P. Alderuccio, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06730542: Recruiting Phase 1 study of CNS Lymphoma, sponsored by Juan P. Alderuccio, MD.
NCT06730542 is a Phase 1 study of CNS Lymphoma that is actively recruiting participants, run by Juan P. Alderuccio, MD. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06730542, a Phase 1 study of CNS Lymphoma, is actively recruiting participants, sponsored by Juan P. Alderuccio, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.
Primary Outcome
The number of participants experiencing dose-limiting toxicities (DLTs) after starting study therapy. Toxicity will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, per physician discretion.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Polatuzumab Vedotin
- DRUG Methotrexate
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 1 |
What NCT06730542 shows while recruiting
NCT06730542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with CNS Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Zanubrutinib is the first listed.
NCT06730542 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06730542 about?
NCT06730542 is a clinical study titled "Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma". The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.
What is the current status of trial NCT06730542?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-04-17. Estimated completion is 2030-04-30.
What conditions does trial NCT06730542 study?
This clinical trial studies the following conditions: CNS Lymphoma.
What interventions are being tested in trial NCT06730542?
The interventions under investigation include: Zanubrutinib (DRUG), Cyclophosphamide (DRUG), Rituximab (DRUG), Polatuzumab Vedotin (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT06730542?
This trial is sponsored by Juan P. Alderuccio, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06730542 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CNS Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06730542's enrollment target sits among peer trials
20 1630th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI